Northern Trust’s Tempest Therapeutics TPST Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $23K | Hold |
14,053
| – | – | ﹤0.01% | 4323 |
|
|
2025
Q4 | $40.3K | Buy |
+14,053
| New | +$99.4K | ﹤0.01% | 4322 |
|
|
2025
Q2 | – | Sell |
-7,645
| Closed | -$73.4K | – | 4492 |
|
|
2025
Q1 | $73.4K | Buy |
7,645
+2,428
| +47% | +$27.5K | ﹤0.01% | 4166 |
|
|
2024
Q4 | $56.6K | Buy |
5,217
+3,651
| +233% | +$47.1K | ﹤0.01% | 4245 |
|
|
2024
Q3 | $28.5K | Hold |
1,566
| – | – | ﹤0.01% | 4294 |
|
|
2024
Q2 | $44.6K | Hold |
1,566
| – | – | ﹤0.01% | 4228 |
|
|
2024
Q1 | $79.6K | Sell |
1,566
-1,018
| -39% | -$51.4K | ﹤0.01% | 4141 |
|
|
2023
Q4 | $148K | Buy |
2,584
+1,541
| +148% | +$73K | ﹤0.01% | 4005 |
|
|
2023
Q3 | $4.13K | Hold |
1,043
| – | – | ﹤0.01% | 4444 |
|
|
2023
Q2 | $17.2K | Hold |
1,043
| – | – | ﹤0.01% | 4431 |
|
|
2023
Q1 | $31.4K | Buy |
+1,043
| New | +$22.9K | ﹤0.01% | 4368 |
|
|
2021
Q2 | – | Sell |
-163
| Closed | -$38K | – | 4632 |
|
|
2021
Q1 | $38K | Sell |
163
-17
| -9% | -$6.87K | ﹤0.01% | 4405 |
|
|
2020
Q4 | $75K | Sell |
180
-31
| -15% | -$10.7K | ﹤0.01% | 4175 |
|
|
2020
Q3 | $67K | Buy |
211
+31
| +17% | +$10.5K | ﹤0.01% | 4053 |
|
|
2020
Q2 | $62K | Sell |
180
-613
| -77% | -$245K | ﹤0.01% | 4017 |
|
|
2020
Q1 | $817K | Buy |
793
+195
| +33% | +$284K | ﹤0.01% | 3300 |
|
|
2019
Q4 | $786K | Buy |
598
+23
| +4% | +$32.4K | ﹤0.01% | 3461 |
|
|
2019
Q3 | $797K | Buy |
575
+363
| +171% | +$586K | ﹤0.01% | 3448 |
|
|
2019
Q2 | $477K | Buy |
+212
| New | +$624K | ﹤0.01% | 3564 |
|
|
2018
Q4 | – | Sell |
-23
| Closed | -$49K | – | 4318 |
|
|
2018
Q3 | $49K | Hold |
23
| – | – | ﹤0.01% | 4136 |
|
|
2018
Q2 | $62K | Hold |
23
| – | – | ﹤0.01% | 4093 |
|
|
2018
Q1 | $56K | Sell |
23
-1
| -4% | -$3K | ﹤0.01% | 4066 |
|
|
2017
Q4 | $97K | Sell |
24
-1
| -4% | -$4.2K | ﹤0.01% | 3977 |
|
|
2017
Q3 | $103K | Sell |
25
-4
| -14% | -$17.1K | ﹤0.01% | 3946 |
|
|
2017
Q2 | $133K | Sell |
29
-91
| -76% | -$385K | ﹤0.01% | 3907 |
|
|
2017
Q1 | $657K | Sell |
120
-62
| -34% | -$289K | ﹤0.01% | 3466 |
|
|
2016
Q4 | $813K | Buy |
182
+2
| +1% | +$24.9K | ﹤0.01% | 3409 |
|
|
2016
Q3 | $3.77M | Buy |
180
+99
| +122% | +$1.79M | ﹤0.01% | 2710 |
|
|
2016
Q2 | $1.23M | Sell |
81
-10
| -11% | -$228K | ﹤0.01% | 3280 |
|
|
2016
Q1 | $2.51M | Sell |
91
-2
| -2% | -$42.3K | ﹤0.01% | 2839 |
|
|
2015
Q4 | $2.67M | Buy |
93
+2
| +2% | +$66K | ﹤0.01% | 2875 |
|
|
2015
Q3 | $2.26M | Buy |
91
+25
| +38% | +$1.68M | ﹤0.01% | 2980 |
|
|
2015
Q2 | $5.58M | Buy |
66
+7
| +12% | +$641K | ﹤0.01% | 2450 |
|
|
2015
Q1 | $6.04M | Buy |
59
+7
| +13% | +$932K | ﹤0.01% | 2389 |
|
|
2014
Q4 | $6.67M | Sell |
52
-1
| -2% | -$73.2K | ﹤0.01% | 2316 |
|
|
2014
Q3 | $2.56M | Buy |
53
+10
| +23% | +$351K | ﹤0.01% | 2936 |
|
|
2014
Q2 | $1.15M | Buy |
43
+3
| +8% | +$70.7K | ﹤0.01% | 3349 |
|
|
2014
Q1 | $1.03M | Buy |
40
+3
| +8% | +$85K | ﹤0.01% | 3388 |
|
|
2013
Q4 | $1M | Hold |
37
| – | – | ﹤0.01% | 3380 |
|
|
2013
Q3 | $1.07M | Buy |
37
+27
| +270% | +$958K | ﹤0.01% | 3311 |
|
|
2013
Q2 | $413K | Buy |
+10
| New | +$376K | ﹤0.01% | 3490 |
|
Other funds holding TPST
VVM
VCM
VFT
SM
TRCT
Northern Trust's TPST Position: Q1 2026 in Review
Northern Trust held its Tempest Therapeutics (TPST) position steady in Q1 2026 at 14,053 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #4323.
Northern Trust first reported a position in TPST in Q2 2013 and has held it in 41 quarters since. The position peaked at $6.67M in Q4 2014. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.
- Northern Trust held 14,053 shares of Tempest Therapeutics worth $23K as of Q1 2026.
- Northern Trust left its Tempest Therapeutics share count unchanged in Q1 2026.
- Tempest Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #4323 holding.
- Northern Trust first reported a position in Tempest Therapeutics in Q2 2013 and has held it in 41 quarters since.
- Northern Trust's Tempest Therapeutics position peaked at $6.67M in Q4 2014.
- 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.